INCR Stock Analysis: Buy, Sell, or Hold?
INCR - Intercure Ltd. Ordinary Shares
$5.17
0.14 (2.78%)
▲
5d:
-4.61%
30d:
-1.34%
90d:
+444.21%
HOLD
MODERATE Confidence
Analysis Updated: Oct 9, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When INCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INCR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INCR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INCR is currently trading at $5.17, which is considered slightly low relative to its 30-day fair value range of $5.17 to $5.40.
Technical Outlook: Technically, INCR is in a strong uptrend. Immediate support is located at $5.01, while resistance sits at $5.48.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $33.56 (+549.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INCR is in a strong uptrend. Immediate support is located at $5.01, while resistance sits at $5.48.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $33.56 (+549.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.17 -
$5.40
Company Quality Score
55/100
(HOLD)
Options IV Signal
33th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 33th percentile)
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 549.1% below Wall St target ($33.56)
- NEUTRAL: Bottoming setup forming (41/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$5.17 -
$5.40
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.65
(12.6%)
Support & Resistance Levels
Support Level
$5.01
Resistance Level
$5.48
Current Trend
Strong Uptrend
Technical data as of
Oct 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.18
Wall Street Target
$33.56
(+549.1%)
Revenue Growth (YoY)
23.9%
Earnings Growth (YoY)
-84.7%
Profit Margin
-13.2%
Share & Embed Analysis
Last updated: October 10, 2026 12:27 PM ET
Data refreshes hourly during market hours. Next update: 1:27 PM
Data refreshes hourly during market hours. Next update: 1:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
28 analysts |
$208 | 54 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 62 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 58 HOLD |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$42 | 57 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 58 HOLD |
